Per Bo Jensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Per Bo Jensen has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Jens Juul Holst
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3 shared publications Christopher B. Newgard
Departments of Pharmacology and Cancer Biology, Medicine, and Biochemistry, Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27704; ‡Department of Internal Medicine, Division of Endocrinology, University of Virginia Medical Center, Charlottesville, VA 22903; §Department of Internal Medicine, University of California, San Francisco, CA 94143; and ¶Section on Islet Transplantation and Cell Biology, Joslin Diabetes Center, Boston, MA 02215
2 shared publicationsHal K. Berman
From the ‡Departments of Biochemistry & Internal Medicine and Touchstone Center for Diabetes Research, University of Texas Southwestern Medical Center, Dallas, Texas 75235, the §Department of Cell Biology, Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, and the ¶Department of Biochemistry, University of Indiana School of Medicine, Indianapolis, Indiana 46202
2 shared publications- Jan Jensen
Hagedorn Research Institute
2 shared publications Lars Thim
2 shared publicationsMads Tang-Christensen
Rheoscience, Glerupvej 2, 2610 Rødovre, Denmark
2 shared publications
Latest Publications
- Open Access
- 10 November 2023
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 65 (1)
Octreotide improves human lymphatic fluid transport a translational trial
Chylothorax is a complex condition and many different pharmacological agents have been tried as treatment. Octreotide is used off-label to treat chylothorax, but the efficacy of octreotide remains unclear. A decrease in lymph production is suggested as the mechanism. In this cross-over study, we explore the direct effect of octreotide on human lymphatic drainage. Pre-clinical: the effect of octreotide on force generation was assessed during acute and prolonged drug incubation on human lymphatic vessels mounted in a myograph. Clinical: in a double-blinded, randomized, cross-over trial including 16 healthy adults, we administered either octreotide or saline as an intravenous infusion for 2.5 h. Near-infrared fluorescence imaging was used to examine spontaneous lymphatic contractions and lymph pressure in peripheral lymphatic vessels and plethysmography was performed to assess the capillary filtration rate, capillary filtration coefficient and isovolumetric pressures of the lower leg. Pre-clinical: human thoracic duct (n = 12) contraction rate was concentration-dependently stimulated by octreotide with a maximum effect at 10 and 100 nmol/l in the myograph chamber. Clinical: spontaneous lymphatic contractions and lymph pressure evaluated by near-infrared fluorescence did not differ between octreotide or placebo (P = 0.36). Plethysmography revealed similar capillary filtration coefficients (P = 0.057), but almost a doubling of the isovolumetric pressures (P = 0.005) during octreotide infusion. Octreotide stimulated lymphatic contractility in the pre-clinical setup but did not affect the spontaneous lymphatic contractions or lymph pressure in healthy individuals. Plethysmography revealed a doubling in the isovolumetric pressure. These results suggest that octreotide increases lymphatic drainage capacity in situations with high lymphatic afterload.
- 10 November 2023
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 65 (1)
Open AccessOctreotide improves human lymphatic fluid transport a translational trial
Chylothorax is a complex condition and many different pharmacological agents have been tried as treatment. Octreotide is used off-label to treat chylothorax, but the efficacy of octreotide remains unclear. A decrease in lymph production is suggested as the mechanism. In this cross-over study, we explore the direct effect of octreotide on human lymphatic drainage. Pre-clinical: the effect of octreotide on force generation was assessed during acute and prolonged drug incubation on human lymphatic vessels mounted in a myograph. Clinical: in a double-blinded, randomized, cross-over trial including 16 healthy adults, we administered either octreotide or saline as an intravenous infusion for 2.5 h. Near-infrared fluorescence imaging was used to examine spontaneous lymphatic contractions and lymph pressure in peripheral lymphatic vessels and plethysmography was performed to assess the capillary filtration rate, capillary filtration coefficient and isovolumetric pressures of the lower leg. Pre-clinical: human thoracic duct (n = 12) contraction rate was concentration-dependently stimulated by octreotide with a maximum effect at 10 and 100 nmol/l in the myograph chamber. Clinical: spontaneous lymphatic contractions and lymph pressure evaluated by near-infrared fluorescence did not differ between octreotide or placebo (P = 0.36). Plethysmography revealed similar capillary filtration coefficients (P = 0.057), but almost a doubling of the isovolumetric pressures (P = 0.005) during octreotide infusion. Octreotide stimulated lymphatic contractility in the pre-clinical setup but did not affect the spontaneous lymphatic contractions or lymph pressure in healthy individuals. Plethysmography revealed a doubling in the isovolumetric pressure. These results suggest that octreotide increases lymphatic drainage capacity in situations with high lymphatic afterload.
- 1 March 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1847 (3) , 328-342
Polyethylenimine architecture-dependent metabolic imprints and perturbation of cellular redox homeostasis
- 1 March 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1847 (3) , 328-342
Polyethylenimine architecture-dependent metabolic imprints and perturbation of cellular redox homeostasis
- Open Access
- 1 March 2012
- Published by Elsevier in Mitochondrion
- Vol. 12 (2) , 328-335
Microscale oxygraphy reveals OXPHOS impairment in MRC mutant cells
- 1 March 2012
- Published by Elsevier in Mitochondrion
- Vol. 12 (2) , 328-335
Open AccessMicroscale oxygraphy reveals OXPHOS impairment in MRC mutant cells
- 8 August 2011
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (s1) , 60-68
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia
We have previously reported severe anorexia abruptly induced in rats 2–3 weeks after they have been transplanted subcutaneously with the glucagonoma MSL‐G‐AN. Vagotomy did not affect the time of onset and severity of anorexia, and the anorectic state resembles hunger with strongly elevated neuropeptide Y (NPY) mRNA levels in the nucleus arcuatus. We now show that circulating levels of bioactive glucagon‐like peptide‐1 (GLP‐1) (7‐36amide) start to increase above control levels exactly at the time of onset of anorexia. At this time‐point, bioactive glucagon as well as total glucagon precursors and GLP‐1 metabolites are already vastly elevated compared to controls. We further show that intravenous administration of very high concentrations of GLP‐1 to hungry schedule‐fed rats causes anorexia in a dose‐dependent manner, which is blocked by the GLP‐1 receptor antagonist exendin (9‐39). GLP‐1 (7‐36amide) has a well‐characterized anorectic effect but also causes taste aversion when administered centrally. The anorectic effect is blocked in rats treated neonatally by monosodium glutamate (MSG). We show that MSG treatment does not prevent the MSL‐G‐AN‐induced anorexia, thereby suggesting a different type of anorectic function. We show a very strong component of taste aversion as anorectic rats, when presented to novel or known alternative food items, will resume normal feeding for 1 day, and then redevelop anorexia. We hypothetize that the anorexia in MSL‐G‐AN tumour‐bearing rats correlates with a foetal processing pattern of proglucagon to both glucagon and GLP‐1 (7‐36amide), and is due to taste aversion. The sudden onset is characterized by a dramatic increase in circulating levels of biologically active GLP‐1 (7‐36amide), suggesting eventual saturation of proteolytic inactivation of its N‐terminus.
- 8 August 2011
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (s1) , 60-68
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia
We have previously reported severe anorexia abruptly induced in rats 2–3 weeks after they have been transplanted subcutaneously with the glucagonoma MSL‐G‐AN. Vagotomy did not affect the time of onset and severity of anorexia, and the anorectic state resembles hunger with strongly elevated neuropeptide Y (NPY) mRNA levels in the nucleus arcuatus. We now show that circulating levels of bioactive glucagon‐like peptide‐1 (GLP‐1) (7‐36amide) start to increase above control levels exactly at the time of onset of anorexia. At this time‐point, bioactive glucagon as well as total glucagon precursors and GLP‐1 metabolites are already vastly elevated compared to controls. We further show that intravenous administration of very high concentrations of GLP‐1 to hungry schedule‐fed rats causes anorexia in a dose‐dependent manner, which is blocked by the GLP‐1 receptor antagonist exendin (9‐39). GLP‐1 (7‐36amide) has a well‐characterized anorectic effect but also causes taste aversion when administered centrally. The anorectic effect is blocked in rats treated neonatally by monosodium glutamate (MSG). We show that MSG treatment does not prevent the MSL‐G‐AN‐induced anorexia, thereby suggesting a different type of anorectic function. We show a very strong component of taste aversion as anorectic rats, when presented to novel or known alternative food items, will resume normal feeding for 1 day, and then redevelop anorexia. We hypothetize that the anorexia in MSL‐G‐AN tumour‐bearing rats correlates with a foetal processing pattern of proglucagon to both glucagon and GLP‐1 (7‐36amide), and is due to taste aversion. The sudden onset is characterized by a dramatic increase in circulating levels of biologically active GLP‐1 (7‐36amide), suggesting eventual saturation of proteolytic inactivation of its N‐terminus.
- Open Access
- 6 December 2010
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 46,p. e2511
Bioenergetic Profile Experiment using C2C12 Myoblast Cells
A description of a method for profiling mitochondrial function in cells is provided. The mitochondrial profile generated provides four...
- 6 December 2010
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 46,p. e2511
Open AccessBioenergetic Profile Experiment using C2C12 Myoblast Cells
A description of a method for profiling mitochondrial function in cells is provided. The mitochondrial profile generated provides four...
- 2 January 2008
- Published by Elsevier in Brain Research
- Vol. 1187, 116-124
Upregulation of the brainstem preproglucagon system in the obese Zucker rat
- 2 January 2008
- Published by Elsevier in Brain Research
- Vol. 1187, 116-124
Upregulation of the brainstem preproglucagon system in the obese Zucker rat
- 1 February 2006
- Published by Cambridge University Press (CUP) in Proceedings of the Nutrition Society
- Vol. 65 (1) , 61-67
Biological effects of fruit and vegetables
A strong and persistent effect of plant-derived foods on the prevention of lifestyle diseases has emerged from observational studies. Several groups of constituents in plants have been identified as potentially health promoting in animal studies, including cholesterol-lowering factors, antioxidants, enzyme inducers, apoptosis inducers etc. In human intervention studies the dose levels achieved tend to be lower than the levels found to be effective in animals and sampling from target organs is often not possible. A controlled dietary human intervention study was performed with forty-three volunteers, providing 600 g fruit and vegetables/d or in the controls a carbohydrate-rich drink to balance energy intake. Surrogate markers of oxidative damage to DNA, protein and lipids, enzymic defence and lipid metabolism were determined in blood and urine. It was found that a high intake of fruit and vegetables tends to increase the stability of lipids towards oxidative damage. Markers of oxidative enzymes indicate a steady increase in glutathione peroxidase (GPX1) activity in erythrocytes during intervention with fruit and vegetables but there is no effect on GPX1 transcription levels in leucocytes. No change occurs in glutathione-conjugating or -reducing enzyme activities in erythrocytes or plasma, and there are no effects on the transcription of genes involved in phase 2 enzyme induction or DNA repair in leucocytes. Fruit and vegetable intake decreases the level of total cholesterol and LDL-cholesterol, but does not affect sex hormones. In conclusion, it has been shown that total cholesterol and LDL-cholesterol, markers of peripheral lipid oxidation, and erythrocyte GPX1 activity are affected by high intakes of fruit and vegetables. This finding provides support for a protective role of dietary fruit and vegetables against CVD.
- 1 February 2006
- Published by Cambridge University Press (CUP) in Proceedings of the Nutrition Society
- Vol. 65 (1) , 61-67
Biological effects of fruit and vegetables
A strong and persistent effect of plant-derived foods on the prevention of lifestyle diseases has emerged from observational studies. Several groups of constituents in plants have been identified as potentially health promoting in animal studies, including cholesterol-lowering factors, antioxidants, enzyme inducers, apoptosis inducers etc. In human intervention studies the dose levels achieved tend to be lower than the levels found to be effective in animals and sampling from target organs is often not possible. A controlled dietary human intervention study was performed with forty-three volunteers, providing 600 g fruit and vegetables/d or in the controls a carbohydrate-rich drink to balance energy intake. Surrogate markers of oxidative damage to DNA, protein and lipids, enzymic defence and lipid metabolism were determined in blood and urine. It was found that a high intake of fruit and vegetables tends to increase the stability of lipids towards oxidative damage. Markers of oxidative enzymes indicate a steady increase in glutathione peroxidase (GPX1) activity in erythrocytes during intervention with fruit and vegetables but there is no effect on GPX1 transcription levels in leucocytes. No change occurs in glutathione-conjugating or -reducing enzyme activities in erythrocytes or plasma, and there are no effects on the transcription of genes involved in phase 2 enzyme induction or DNA repair in leucocytes. Fruit and vegetable intake decreases the level of total cholesterol and LDL-cholesterol, but does not affect sex hormones. In conclusion, it has been shown that total cholesterol and LDL-cholesterol, markers of peripheral lipid oxidation, and erythrocyte GPX1 activity are affected by high intakes of fruit and vegetables. This finding provides support for a protective role of dietary fruit and vegetables against CVD.
- 9 May 2005
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 102 (20) , 7297-7302
The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells
We have previously described rat insulinoma INS-1-derived cell lines with robust or poor glucose-stimulated insulin secretion (GSIS). In the current study, we have further resolved these lines into three classes: class 1, glucose-unresponsive/glucagon-expressing; class 2, glucose-unresponsive/glucagon-negative; and class 3, glucose-responsive/glucagon-negative. The transcription factor Nkx2.2 was expressed with relative abundance of 3.3, 1.0, and 1.0 in class 1, class 2, and class 3 cells, respectively, whereas Nkx6.1 expression had the opposite trend: 1.0, 2.6, and 6.4 in class 1, class 2, and class 3 cells, respectively. In class 1 cells, overexpressed Nkx6.1 suppressed glucagon expression but did not affect the levels of several other prominent beta cell transcription factors. RNA interference (RNAi)-mediated suppression of Nkx6.1 in class 3 cells resulted in a doubling of glucagon mRNA, with no effect on Pdx1 levels, whereas suppression of Pdx1 in class 3 cells caused a 12-fold increase in glucagon transcript levels, demonstrating independent effects of Nkx6.1 and Pdx1 on glucagon expression in beta cell lines. RNAi-mediated suppression of Nkx6.1 expression in class 3 cells also caused a decrease in GSIS from 13.9- to 3.7-fold, whereas suppression of Pdx1 reduced absolute amounts of insulin secretion without affecting fold response. Finally, RNAi-mediated suppression of Nkx6.1 mRNA in primary rat islets was accompanied by a significant decrease in GSIS relative to control cells. In sum, our studies have revealed roles for Nkx6.1 in suppression of glucagon expression and control of GSIS in islet beta cells.
- 9 May 2005
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 102 (20) , 7297-7302
The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells
We have previously described rat insulinoma INS-1-derived cell lines with robust or poor glucose-stimulated insulin secretion (GSIS). In the current study, we have further resolved these lines into three classes: class 1, glucose-unresponsive/glucagon-expressing; class 2, glucose-unresponsive/glucagon-negative; and class 3, glucose-responsive/glucagon-negative. The transcription factor Nkx2.2 was expressed with relative abundance of 3.3, 1.0, and 1.0 in class 1, class 2, and class 3 cells, respectively, whereas Nkx6.1 expression had the opposite trend: 1.0, 2.6, and 6.4 in class 1, class 2, and class 3 cells, respectively. In class 1 cells, overexpressed Nkx6.1 suppressed glucagon expression but did not affect the levels of several other prominent beta cell transcription factors. RNA interference (RNAi)-mediated suppression of Nkx6.1 in class 3 cells resulted in a doubling of glucagon mRNA, with no effect on Pdx1 levels, whereas suppression of Pdx1 in class 3 cells caused a 12-fold increase in glucagon transcript levels, demonstrating independent effects of Nkx6.1 and Pdx1 on glucagon expression in beta cell lines. RNAi-mediated suppression of Nkx6.1 expression in class 3 cells also caused a decrease in GSIS from 13.9- to 3.7-fold, whereas suppression of Pdx1 reduced absolute amounts of insulin secretion without affecting fold response. Finally, RNAi-mediated suppression of Nkx6.1 mRNA in primary rat islets was accompanied by a significant decrease in GSIS relative to control cells. In sum, our studies have revealed roles for Nkx6.1 in suppression of glucagon expression and control of GSIS in islet beta cells.
- 1 April 2002
- Published by Elsevier in European Journal of Pharmacology
- Vol. 440 (2-3) , 159-172
Ups and downs for neuropeptides in body weight homeostasis: pharmacological potential of cocaine amphetamine regulated transcript and pre-proglucagon-derived peptides
- 1 April 2002
- Published by Elsevier in European Journal of Pharmacology
- Vol. 440 (2-3) , 159-172
Ups and downs for neuropeptides in body weight homeostasis: pharmacological potential of cocaine amphetamine regulated transcript and pre-proglucagon-derived peptides
- Open Access
- 1 August 2000
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 275 (34) , 26396-26403
Distinctive Regulatory and Metabolic Properties of Glycogen-targeting Subunits of Protein Phosphatase-1 (PTG, GL, GM/RGl) Expressed in Hepatocytes
- 1 August 2000
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 275 (34) , 26396-26403
Open AccessDistinctive Regulatory and Metabolic Properties of Glycogen-targeting Subunits of Protein Phosphatase-1 (PTG, GL, GM/RGl) Expressed in Hepatocytes